Dexamethasone-Loaded Block Copolymer Nanoparticles Induce Leukemia Cell Death and Enhance Therapeutic Efficacy: A Novel Application in Pediatric Nanomedicine

Department of Materials Science and Engineering, University of Delaware , 201 DuPont Hall, Newark, Delaware 19716-1501, United States.
Molecular Pharmaceutics (Impact Factor: 4.38). 06/2013; 10(6):2199-2210. DOI: 10.1021/mp300350e
Source: PubMed


Nanotechnology approaches have tremendous potential for enhancing treatment efficacy with lower doses of chemotherapeutics. Nanoparticle (NP)-based drug delivery approaches are poorly developed for childhood leukemia. Dexamethasone (Dex) is one of the most common chemotherapeutic drugs used in the treatment of childhood leukemia. In this study, we encapsulated Dex in polymeric NPs and validated their antileukemic potential in vitro and in vivo. NPs with an average diameter of 110 nm were assembled from an amphiphilic block copolymer of poly(ethylene glycol) (PEG) and poly(ε-caprolactone) (PCL) bearing pendant cyclic ketals (ECT2). The blank NPs were nontoxic to cultured cells in vitro and to mice in vivo. Encapsulation of Dex into the NPs (Dex-NP) did not compromise the bioactivity of the drug. Dex-NPs induced glucocorticoid phosphorylation and showed cytotoxicity similar to the free Dex in leukemic cells. Studies using NPs labeled with fluorescent dyes revealed leukemic cell surface binding and internalization. In vivo biodistribution studies showed NP accumulation in the liver and spleen with subsequent clearance of the particles with time. In a preclinical model of leukemia, Dex-NPs significantly improved the quality of life and survival of mice as compared to the free drug. To our knowledge, this is the first report showing the efficacy of polymeric NPs to deliver Dex to potentially treat childhood leukemia and reveals that low doses of Dex should be sufficient for inducing cell death and improving survival.

Download full-text


Available from: Vinu Krishnan, Dec 19, 2014
1 Follower
44 Reads
  • Source
    • "Several strategies including the use of nanoparticles have been proposed to avoid these concerns including its long-term impairment of physiological functions (22). A variety of nanoparticles, including dendrimers, gold particles, liposomes, micelles, and polymers have been described to improve the bioavailability or the therapeutic efficacy of currently used anti-cancer agents (14, 16). These nanodelivery systems have yet to be evaluated in pediatric leukemia patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The two major forms of leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), account for about one-third of the malignancies diagnosed in children. Despite the marked successes in ALL and AML treatment, concerns remain regarding the occurrence of resistant disease in subsets of patients, the residual effects of therapy that often persist for decades beyond the cessation of treatment. Therefore, new approaches are needed to reduce or to avoid off target toxicities, associated with chemotherapy and their long-term residual effects. Recently, nanotechnology has been employed to enhance cancer therapy, via improving the bioavailability and therapeutic efficacy of anti-cancer agents. While in the last several years, numerous review articles appeared detailing the size, composition, assembly, and performance evaluation of different types of drug carrying nanoparticles, the description and evaluation of lipoprotein-based drug carriers have been conspicuously absent from most of these major reviews. The current review focuses on such information regarding nanoparticles with an emphasis on high density lipoprotein-based drug delivery systems to examine their potential role(s) in the enhanced treatment of children with leukemia.
    Frontiers in Oncology 05/2014; 4:101. DOI:10.3389/fonc.2014.00101
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Dexamethasone (DXM) is a synthetic glucocorticoid with anti-inflammatory properties. Targeted delivery of dexamethasone to inflammatory cells, e.g. macrophages and Kupffer cells represents a promising approach to minimize side effects. The aim of the present study was to induce a targeted transport of novel DXM-based biodegradable nanocapsules to phagocytic cells. Nanocapsules (NCs) consisting of a hydroxyethylated glucose polymer (hydroxyethyl starch, HES) shell with encapsulated DXM and NCs synthesized exclusively in inverse miniemulsion out of DXM were investigated. Non-parenchymal murine liver cells served as target cells. HES-DXM NCs were predominantly incorporated by Kupffer cells (KCs). In contrast, DXM NCs were phagocytized by KCs and endothelial cells. The release of the NC-content was confirmed by incorporation of CellTracker™ into the NCs. Uptake of DXM NCs by Kupffer cells reduced significantly the release of inflammatory cytokines in response to LPS stimulation. Importantly, the DXM NCs consisting exclusively out of a dexamethasone shell offer the potential to serve as carriers for additional therapeutics. From the clinical editor: In this paper, nanocapsule-based targeted delivery of dexamethasone to inflammatory cells is presented as a promising approach to minimize side effects and increase efficacy of this anti-inflammatory clinically used corticosteroid.
    Nanomedicine: nanotechnology, biology, and medicine 05/2013; 9(8). DOI:10.1016/j.nano.2013.05.005 · 6.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Block copolymers of poly(ethylene glycol) (PEG) and poly(ε -caprolactone) (PCL) with chemically addressable functional groups were synthesized and characterized. Ring opening polymerization of ε -caprolactone (CL) and 1,4,8-trioxaspiro-[4,6]-9-undecanone (TSU) using α-methoxy, ω-hydroxyl poly(ethylene glycol) (mPEG) as the initiator afforded a copolymer with cyclic ketals being randomly distributed in the hydrophobic PCL block. At an initiator/catalyst molar ratio of 10/1 and a TSU/CL weight ratio of 1/4, a ketal-carrying copolymer (ECT2-CK) with Mn of 52 kDa and a ketal content of 15 mol% was obtained. Quantitative side chain deacetalization revealed the reactive ketones without noticeable polymer degradation. In our study, 10 mol% of cyclic ketals were deprotected and the ketone-containing copolymer was designated as ECT2-CO. Reaction of ECT2-CO with 2-(2-(aminooxy)acetoxy)-ethyl acrylate gave rise to an acrylated product (ECT2-AC) containing an estimated 3-5 acrylate groups per chain. UV-initiated radical polymerization of ECT2-AC in dichloromethane resulted in a crosslinked network (xECT2-AC). Thermal and morphological analyses employing Differential Scanning Calorimetry (DSC) and Atomic Force Microscopy (AFM) operated in PeakForce Tapping mode revealed the semicrystalline nature of the network, containing stiff crystalline lamellae dispersed in a softer amorphous interstitial. Macroscopic and nanoscale mechanical characterizations showed that ECT2-CK exhibited a significantly lower modulus than PCL of a similar molecular weight. While ECT2-CK undergoes a plastic deformation with a distinct yield point and a cold drawing region, xECT2-AC exhibited a compliant, elastomeric deformation with a Young's modulus of 0.5 ± 0.1 MPa at 37 °C. When properly processed, the crosslinked network exhibited shape memory behaviors, with shape fixity and shape recovery values close to 1 and a shape recovery time of less than 4 s at 37 °C. In vitro studies showed that xECT2-AC films did not induce any cytotoxic effects to the cultured mesenchymal stem cells. The crosslinkable polyester copolymers can be potentially used as tissue engineering scaffolds and minimally invasive medical devices.
    Acta biomaterialia 06/2013; 9(9). DOI:10.1016/j.actbio.2013.06.005 · 6.03 Impact Factor
Show more